Objectif Studies have demonstrated the importance of CD73 in the spread of cancer. Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microenvironment, and contributing to tumor proliferation and dissemination. Neutralizing its activity represents a highly potent and innovative therapy.Following on the recent success of mAbs targeting immune checkpoint (PD1, CTLA4), TumAdoR aims to discover, characterize and produce humanized anti-hCD73 mAbs that will be assessed for their efficacy and safety in relevant mouse preclinical tumor models. It will result in the development of anti-CD73 drug candidates that will strengthen the immune system, stop cancer cell progression and prevent relapse through restoration of immune memory. TumAdoR aims at paving the way to first-in-human clinical trials of potent mAb candidates, and validating a new cancer immunotherapy, suitable for a wide range of cancers.More precisely, TumAdoR will:•Reinforce knowledge about CD73 role as an immune checkpoint target•Correlate CD73 expression with clinical outcome and validate the tumor patients most likely to benefit from CD73 blockade•Discover and develop mAbs neutralizing hCD73•Develop relevant preclinical tumor models to validate the in vivo efficacy and safety of anti-CD73 mAbs candidate(s)•Develop and standardize tools to assess CD73 expression, and monitor immune parameters in patientsTumAdoR addresses topic 1 by developing antibodies neutralizing CD73, and topic 3 by fighting against immune evasion in tumor host microenvironment. The high-level consortium including 3 SMEs possesses all the scientific and clinical expertises, industrial competences, biological and enzymatic assays, biological and clinical resources, and preclinical models to discover and produce mAbs, and investigate the functions of CD73, and the therapeutic impact of its neutralization. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.4.1-2 - Strengthening the cancer patient's immune system Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD Contribution de l’UE € 1 863 991,62 Adresse RUE LAENNEC 28 69373 Lyon France Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Rhône Type d’activité Research Organisations Contact administratif Marina Rousseau (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (7) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire INNATE PHARMA France Contribution de l’UE € 1 566 684,40 Adresse AVENUE DE LUMINY 117 13009 Marseille Voir sur la carte Région Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Nicolas Dams (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée TURUN YLIOPISTO Finlande Contribution de l’UE € 781 674,80 Adresse YLIOPISTONMAKI 20014 Turku Voir sur la carte Région Manner-Suomi Etelä-Suomi Varsinais-Suomi Type d’activité Higher or Secondary Education Establishments Contact administratif Mari Riipinen (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée GENEWAKE GMBH Participation terminée Allemagne Contribution de l’UE € 173 432,96 Adresse Floriansbogen 2-4 82061 NEURIED Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Robert Loewe (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITE DE LAUSANNE Suisse Contribution de l’UE € 719 116,22 Adresse Quartier Unil-Centre Bâtiment Unicentre 1015 Lausanne Voir sur la carte Région Schweiz/Suisse/Svizzera Région lémanique Vaud Type d’activité Higher or Secondary Education Establishments Contact administratif Pedro Romero (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée THE UNIVERSITY OF TEXAS SYSTEM États-Unis Contribution de l’UE € 515 590,00 Adresse COLORADO STREET 601 78701 2982 Austin Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Tyler Curiel (Dr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée POLYGENE AG Suisse Contribution de l’UE € 114 400,00 Adresse RIEDMATTSTRASSE 9 8153 Rümlang Voir sur la carte Région Schweiz/Suisse/Svizzera Zürich Zürich Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Stefan Selbert (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée AYMING France Contribution de l’UE € 244 000,00 Adresse RUE CHAPTAL 114 92300 Levallois-Perret Voir sur la carte Région Ile-de-France Ile-de-France Hauts-de-Seine Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Fabienne Brutin (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée